Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using 82 Rb PET/CT
Our aim was to determine if end-stage liver disease (ESLD) is associated with an attenuated response to vasodilator-stress or dobutamine-stress using Rb-PET MPI with blood flow quantification. Pre-liver transplant patients who had a normal dipyridamole-stress (n = 27) or dobutamine-stress (n = 26) R...
Gespeichert in:
| Veröffentlicht in: | Journal of nuclear cardiology 2020-12, Vol.27 (6), p.2048 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 2048 |
| container_title | Journal of nuclear cardiology |
| container_volume | 27 |
| creator | Abele, Jonathan T Raubenheimer, Monique Bain, Vincent G Wandzilak, Greg AlHulaimi, Naji Coulden, Richard deKemp, Robert A Klein, Ran Williams, Randall G Warshawski, Robert S Lalonde, Lucille D |
| description | Our aim was to determine if end-stage liver disease (ESLD) is associated with an attenuated response to vasodilator-stress or dobutamine-stress using
Rb-PET MPI with blood flow quantification.
Pre-liver transplant patients who had a normal dipyridamole-stress (n = 27) or dobutamine-stress (n = 26)
Rb PET/CT MPI study with no identifiable coronary artery calcium were identified retrospectively and compared to a prospectively identified low-risk of liver disease dipyridamole-stress control group (n = 20). The dipyridamole-stress liver disease group had a lower myocardial flow reserve (MFR) (1.89 ± 0.79) than the control group (2.79 ± 0.96, P |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_30456495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30456495</sourcerecordid><originalsourceid>FETCH-pubmed_primary_304564953</originalsourceid><addsrcrecordid>eNqFT8tuwjAQtCpVQFt-odofiBoIRs0ZUfVIq9yjDd7AIseOvHYQH8L_NqLl3NNoXhrNg5otdLHM1lovpupJ5JTneVmU5URNi3yl16tSz9T1K6GLHDHyQNBY7w201p-BBrRpVL0D38KA4g3bG88kBhKBve96DGTgzPEIxjcpYseO7j476McCuSi_EXJm9PBAYMexAIaFUAiSsDvA-xK-G9htq7dN9aIeW7RC8z98Vq8f22rzmfWp6cjUfeAOw6W-_yj-DfwAEJtWMw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using 82 Rb PET/CT</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Abele, Jonathan T ; Raubenheimer, Monique ; Bain, Vincent G ; Wandzilak, Greg ; AlHulaimi, Naji ; Coulden, Richard ; deKemp, Robert A ; Klein, Ran ; Williams, Randall G ; Warshawski, Robert S ; Lalonde, Lucille D</creator><creatorcontrib>Abele, Jonathan T ; Raubenheimer, Monique ; Bain, Vincent G ; Wandzilak, Greg ; AlHulaimi, Naji ; Coulden, Richard ; deKemp, Robert A ; Klein, Ran ; Williams, Randall G ; Warshawski, Robert S ; Lalonde, Lucille D</creatorcontrib><description>Our aim was to determine if end-stage liver disease (ESLD) is associated with an attenuated response to vasodilator-stress or dobutamine-stress using
Rb-PET MPI with blood flow quantification.
Pre-liver transplant patients who had a normal dipyridamole-stress (n = 27) or dobutamine-stress (n = 26)
Rb PET/CT MPI study with no identifiable coronary artery calcium were identified retrospectively and compared to a prospectively identified low-risk of liver disease dipyridamole-stress control group (n = 20). The dipyridamole-stress liver disease group had a lower myocardial flow reserve (MFR) (1.89 ± 0.79) than the control group (2.79 ± 0.96, P < .05). The dobutamine-stress group had a higher MFR than both other groups (3.69 ± 1.49, P < .05). A moderate negative correlation between MELD score and MFR was demonstrated for the dipyridamole-stress liver disease group (r = - 0.473, P < .05). This correlation was not observed for the dobutamine-stress liver disease group (r = - 0.253, P = .21). The liver failure group as a whole (n = 53) had a higher resting myocardial blood flow (0.97 ± 0.33 mL/min/g) than the control group (0.82 ± 0.26, P < .05).
Dipyridamole demonstrates an attenuated vasodilatory response in ESLD patients compared to a non-ESLD control group related to higher resting blood flow and comparatively reduced stress blood flow. Dobutamine does not demonstrate this effect implying it may be the preferred pharmacologic MPI stress agent for ESLD patients.</description><identifier>EISSN: 1532-6551</identifier><identifier>PMID: 30456495</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Coronary Circulation - physiology ; Dipyridamole ; Dobutamine ; End Stage Liver Disease - diagnostic imaging ; Female ; Humans ; Liver Failure - diagnostic imaging ; Liver Failure - surgery ; Liver Transplantation ; Male ; Middle Aged ; Myocardial Perfusion Imaging - methods ; Positron Emission Tomography Computed Tomography - methods ; Prospective Studies ; Regression Analysis ; Retrospective Studies ; Rubidium Radioisotopes ; Severity of Illness Index ; Vasodilation ; Vasodilator Agents</subject><ispartof>Journal of nuclear cardiology, 2020-12, Vol.27 (6), p.2048</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30456495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abele, Jonathan T</creatorcontrib><creatorcontrib>Raubenheimer, Monique</creatorcontrib><creatorcontrib>Bain, Vincent G</creatorcontrib><creatorcontrib>Wandzilak, Greg</creatorcontrib><creatorcontrib>AlHulaimi, Naji</creatorcontrib><creatorcontrib>Coulden, Richard</creatorcontrib><creatorcontrib>deKemp, Robert A</creatorcontrib><creatorcontrib>Klein, Ran</creatorcontrib><creatorcontrib>Williams, Randall G</creatorcontrib><creatorcontrib>Warshawski, Robert S</creatorcontrib><creatorcontrib>Lalonde, Lucille D</creatorcontrib><title>Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using 82 Rb PET/CT</title><title>Journal of nuclear cardiology</title><addtitle>J Nucl Cardiol</addtitle><description>Our aim was to determine if end-stage liver disease (ESLD) is associated with an attenuated response to vasodilator-stress or dobutamine-stress using
Rb-PET MPI with blood flow quantification.
Pre-liver transplant patients who had a normal dipyridamole-stress (n = 27) or dobutamine-stress (n = 26)
Rb PET/CT MPI study with no identifiable coronary artery calcium were identified retrospectively and compared to a prospectively identified low-risk of liver disease dipyridamole-stress control group (n = 20). The dipyridamole-stress liver disease group had a lower myocardial flow reserve (MFR) (1.89 ± 0.79) than the control group (2.79 ± 0.96, P < .05). The dobutamine-stress group had a higher MFR than both other groups (3.69 ± 1.49, P < .05). A moderate negative correlation between MELD score and MFR was demonstrated for the dipyridamole-stress liver disease group (r = - 0.473, P < .05). This correlation was not observed for the dobutamine-stress liver disease group (r = - 0.253, P = .21). The liver failure group as a whole (n = 53) had a higher resting myocardial blood flow (0.97 ± 0.33 mL/min/g) than the control group (0.82 ± 0.26, P < .05).
Dipyridamole demonstrates an attenuated vasodilatory response in ESLD patients compared to a non-ESLD control group related to higher resting blood flow and comparatively reduced stress blood flow. Dobutamine does not demonstrate this effect implying it may be the preferred pharmacologic MPI stress agent for ESLD patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Coronary Circulation - physiology</subject><subject>Dipyridamole</subject><subject>Dobutamine</subject><subject>End Stage Liver Disease - diagnostic imaging</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Failure - diagnostic imaging</subject><subject>Liver Failure - surgery</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Perfusion Imaging - methods</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Prospective Studies</subject><subject>Regression Analysis</subject><subject>Retrospective Studies</subject><subject>Rubidium Radioisotopes</subject><subject>Severity of Illness Index</subject><subject>Vasodilation</subject><subject>Vasodilator Agents</subject><issn>1532-6551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFT8tuwjAQtCpVQFt-odofiBoIRs0ZUfVIq9yjDd7AIseOvHYQH8L_NqLl3NNoXhrNg5otdLHM1lovpupJ5JTneVmU5URNi3yl16tSz9T1K6GLHDHyQNBY7w201p-BBrRpVL0D38KA4g3bG88kBhKBve96DGTgzPEIxjcpYseO7j476McCuSi_EXJm9PBAYMexAIaFUAiSsDvA-xK-G9htq7dN9aIeW7RC8z98Vq8f22rzmfWp6cjUfeAOw6W-_yj-DfwAEJtWMw</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Abele, Jonathan T</creator><creator>Raubenheimer, Monique</creator><creator>Bain, Vincent G</creator><creator>Wandzilak, Greg</creator><creator>AlHulaimi, Naji</creator><creator>Coulden, Richard</creator><creator>deKemp, Robert A</creator><creator>Klein, Ran</creator><creator>Williams, Randall G</creator><creator>Warshawski, Robert S</creator><creator>Lalonde, Lucille D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>202012</creationdate><title>Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using 82 Rb PET/CT</title><author>Abele, Jonathan T ; Raubenheimer, Monique ; Bain, Vincent G ; Wandzilak, Greg ; AlHulaimi, Naji ; Coulden, Richard ; deKemp, Robert A ; Klein, Ran ; Williams, Randall G ; Warshawski, Robert S ; Lalonde, Lucille D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_304564953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Coronary Circulation - physiology</topic><topic>Dipyridamole</topic><topic>Dobutamine</topic><topic>End Stage Liver Disease - diagnostic imaging</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Failure - diagnostic imaging</topic><topic>Liver Failure - surgery</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Perfusion Imaging - methods</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Prospective Studies</topic><topic>Regression Analysis</topic><topic>Retrospective Studies</topic><topic>Rubidium Radioisotopes</topic><topic>Severity of Illness Index</topic><topic>Vasodilation</topic><topic>Vasodilator Agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abele, Jonathan T</creatorcontrib><creatorcontrib>Raubenheimer, Monique</creatorcontrib><creatorcontrib>Bain, Vincent G</creatorcontrib><creatorcontrib>Wandzilak, Greg</creatorcontrib><creatorcontrib>AlHulaimi, Naji</creatorcontrib><creatorcontrib>Coulden, Richard</creatorcontrib><creatorcontrib>deKemp, Robert A</creatorcontrib><creatorcontrib>Klein, Ran</creatorcontrib><creatorcontrib>Williams, Randall G</creatorcontrib><creatorcontrib>Warshawski, Robert S</creatorcontrib><creatorcontrib>Lalonde, Lucille D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of nuclear cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abele, Jonathan T</au><au>Raubenheimer, Monique</au><au>Bain, Vincent G</au><au>Wandzilak, Greg</au><au>AlHulaimi, Naji</au><au>Coulden, Richard</au><au>deKemp, Robert A</au><au>Klein, Ran</au><au>Williams, Randall G</au><au>Warshawski, Robert S</au><au>Lalonde, Lucille D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using 82 Rb PET/CT</atitle><jtitle>Journal of nuclear cardiology</jtitle><addtitle>J Nucl Cardiol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>27</volume><issue>6</issue><spage>2048</spage><pages>2048-</pages><eissn>1532-6551</eissn><abstract>Our aim was to determine if end-stage liver disease (ESLD) is associated with an attenuated response to vasodilator-stress or dobutamine-stress using
Rb-PET MPI with blood flow quantification.
Pre-liver transplant patients who had a normal dipyridamole-stress (n = 27) or dobutamine-stress (n = 26)
Rb PET/CT MPI study with no identifiable coronary artery calcium were identified retrospectively and compared to a prospectively identified low-risk of liver disease dipyridamole-stress control group (n = 20). The dipyridamole-stress liver disease group had a lower myocardial flow reserve (MFR) (1.89 ± 0.79) than the control group (2.79 ± 0.96, P < .05). The dobutamine-stress group had a higher MFR than both other groups (3.69 ± 1.49, P < .05). A moderate negative correlation between MELD score and MFR was demonstrated for the dipyridamole-stress liver disease group (r = - 0.473, P < .05). This correlation was not observed for the dobutamine-stress liver disease group (r = - 0.253, P = .21). The liver failure group as a whole (n = 53) had a higher resting myocardial blood flow (0.97 ± 0.33 mL/min/g) than the control group (0.82 ± 0.26, P < .05).
Dipyridamole demonstrates an attenuated vasodilatory response in ESLD patients compared to a non-ESLD control group related to higher resting blood flow and comparatively reduced stress blood flow. Dobutamine does not demonstrate this effect implying it may be the preferred pharmacologic MPI stress agent for ESLD patients.</abstract><cop>United States</cop><pmid>30456495</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1532-6551 |
| ispartof | Journal of nuclear cardiology, 2020-12, Vol.27 (6), p.2048 |
| issn | 1532-6551 |
| language | eng |
| recordid | cdi_pubmed_primary_30456495 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Coronary Circulation - physiology Dipyridamole Dobutamine End Stage Liver Disease - diagnostic imaging Female Humans Liver Failure - diagnostic imaging Liver Failure - surgery Liver Transplantation Male Middle Aged Myocardial Perfusion Imaging - methods Positron Emission Tomography Computed Tomography - methods Prospective Studies Regression Analysis Retrospective Studies Rubidium Radioisotopes Severity of Illness Index Vasodilation Vasodilator Agents |
| title | Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using 82 Rb PET/CT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A00%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quantitative%20blood%20flow%20evaluation%20of%20vasodilation-stress%20compared%20with%20dobutamine-stress%20in%20patients%20with%20end-stage%20liver%20disease%20using%2082%20Rb%20PET/CT&rft.jtitle=Journal%20of%20nuclear%20cardiology&rft.au=Abele,%20Jonathan%20T&rft.date=2020-12&rft.volume=27&rft.issue=6&rft.spage=2048&rft.pages=2048-&rft.eissn=1532-6551&rft_id=info:doi/&rft_dat=%3Cpubmed%3E30456495%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30456495&rfr_iscdi=true |